Arrowhead Pharmaceuticals (ARWR) Receives a Buy from RBC Capital

In a report released on January 7, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a price target of $42.00. The company’s shares closed last Wednesday at $19.75.

According to TipRanks, Issi is an analyst with an average return of -17.7% and a 22.62% success rate. Issi covers the Healthcare sector, focusing on stocks such as RegenXBio, Alnylam Pharma, and BioMarin Pharmaceutical.

Arrowhead Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $42.33, an 114.33% upside from current levels. In a report released on January 2, B.Riley Financial also reiterated a Buy rating on the stock with a $51.00 price target.

The company has a one-year high of $39.83 and a one-year low of $17.05. Currently, Arrowhead Pharmaceuticals has an average volume of 1.46M.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARWR in relation to earlier this year. Earlier this month, Kenneth Allen Myszkowski, the CFO of ARWR sold 10,000.00 shares for a total of $196,900.00.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Arrowhead Pharmaceuticals (ARWR) Company Description:

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.